Document is current
Any future updates will be listed below
-
Authors
Takano, Tomotsugu
Tsubouchi, Kazuya
Hamada, Naoki
Ichiki, Katsuyuki
Torii, Ryo
Takata, Shohei
Kawakami, Satoru
Nakagaki, Noriaki
Yoshida, Makoto
Kitasato, Yasuhiko
Tobino, Kazunori
Harada, Eiji
Ishii, Hiroshi
Wataya, Hiroshi
Maeyama, Takashige
Fujita, Masaki
Yatera, Kazuhiro
Okamoto, Masaki
Yabuuchi, Hidetake
Kiyomi, Fumiaki
Tokunaga, Shoji
Nakanishi, Yoichi
Okamoto, Isamu
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim
the Ministry of Education, Culture, Sports, Science and Technology: the broad-area, network-based project to drive clinical research at Kyushu University Hospital
the Diffuse Lung Diseases Research Group from the Ministry of Health, Labor and Welfare, Japan
- License Information
-
More Information
Article History
Received: 8 March 2024
Accepted: 16 October 2024
First Online: 6 November 2024
Declarations
:
: This study involves human participants and this prospective, multi-center　observational study was approved by the Institutional Review Board of Kyushu University (#25–135, August 23, 2013; #555-00, August 27, 2013) and by the institutional review boards of all participating hospitals. Participants provided informed consent before participating in the study.
: Not applicable since there are no details on individuals reported within the manuscript.
: STakata has received personal fees from AstraZeneca, Nippon Boehringer Ingelheim, Novartis, GSK, and Teijin Pharma. KY has received personal fees from Nippon Boehringer Ingelheim, GSK and Teijin Pharma. MO has received personal fees from Nippon Boehringer Ingelheim. IO has received personal fees from AstraZeneca, Nippon Boehringer Ingelheim and Novartis.
